Clinical Guide to ABO-Incompatible Allogeneic Stem Cell Transplantation
Reads0
Chats0
TLDR
Practical approaches to screening for and managing ABO-incompatible HCT are described, with the goal of reducing preventable morbidity and mortality after transplantation.About:
This article is published in Biology of Blood and Marrow Transplantation.The article was published on 2013-08-01 and is currently open access. It has received 114 citations till now. The article focuses on the topics: Transplantation & ABO blood group system.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria.
Journal ArticleDOI
Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition
Joseph E. Schwartz,Anand Padmanabhan,Nicole A. Aqui,Rasheed A. Balogun,Laura Connelly-Smith,Meghan Delaney,Nancy M. Dunbar,Volker Witt,Yanyun Wu,Beth H. Shaz,Beth H. Shaz,Beth H. Shaz +11 more
Journal ArticleDOI
Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes
Lawrence Chang,David Frame,Thomas Braun,Erin Gatza,David A. Hanauer,Shuang G. Zhao,John M. Magenau,Kathryn Schultz,Hemasri Tokala,James L.M. Ferrara,John E. Levine,Pavan Reddy,Sophie Paczesny,Sung Won Choi +13 more
TL;DR: The results illustrate the clinical significance and prognostic impact of ES on allogeneic HCT outcomes and suggest the need for a prospective approach of collecting clinical features combined with correlative laboratory analyses to better characterize ES.
Journal ArticleDOI
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.
TL;DR: Successful treatment with daratumumab is described in a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation in a 72-year-old man with the myelodysplastic syndrome.
References
More filters
Journal ArticleDOI
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
Shimon Slavin,Arnon Nagler,Ella Naparstek,Yossi Kapelushnik,Memet Aker,Gabriel Cividalli,G. Varadi,Mark Kirschbaum,Aliza Ackerstein,Simcha Samuel,Avraham Amar,Chaim Brautbar,Ofira Ben-Tal,Amiram Eldor,Reuven Or +14 more
TL;DR: Preliminary data in 26 patients with standard indications for allogeneic BMT suggest that nonmyeloablative conditioning including fludarabine, anti-T-lymphocyte globulin, and low-dose busulfan is extremely well tolerated, with no severe procedure-related toxicity.
Journal ArticleDOI
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients
Maria Rosa Costanzo,Anne I. Dipchand,Randall C. Starling,Allen S. Anderson,Michael Chan,Shashank Desai,Savitri Fedson,Patrick W. Fisher,Gonzalo Gonzales-Stawinski,Luigi Martinelli,David C. McGiffin,Jon Smith,David O. Taylor,Bruno Meiser,Steven A. Webber,David A. Baran,Michael P. Carboni,Thomas J. Dengler,David L. Feldman,Maria Frigerio,Abdallah G. Kfoury,Daniel Kim,Jon A. Kobashigawa,Michael A. Shullo,Josef Stehlik,Jeffrey J. Teuteberg,Patricia A. Uber,Andreas Zuckermann,Sharon A. Hunt,Michael Burch,Geetha Bhat,Charles E. Canter,Richard E. Chinnock,Marisa G. Crespo-Leiro,Reynolds M. Delgado,Fabienne Dobbels,Kathleen L. Grady,W. Kao,Jaqueline Lamour,Gareth Parry,Jignesh Patel,Daniela Pini,Jeffrey A. Towbin,Gene Wolfel,Diego H. Delgado,Howard J. Eisen,Lee R. Goldberg,Jeff Hosenpud,Maryl R. Johnson,Anne Keogh,Clive Lewis,John B. O'Connell,Joseph G. Rogers,Heather J. Ross,Stuart D. Russell,Johan Vanhaecke,Amanda W. Rowe +56 more
TL;DR: Institutional Affiliations Chair Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA Task Force 1 Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland Clinic Foundation, Cleveland, Ohio, USA; Starlings R: University of Chicago, Chicago, Illinois,USA; Chan M: university of Alberta, Edmonton, Alberta, Canada ; Desai S: Inova Fairfax Hospital, Fairfax, Virginia, USA.
Journal ArticleDOI
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells
Hal E. Broxmeyer,Gordon W. Douglas,Giao Hangoc,Scott Cooper,Judith Bard,Denis English,Margaret Arny,Lewis Thomas,Edward A. Boyse +8 more
TL;DR: It was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy.
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
Craig Kollman,Craig W. S. Howe,Claudio Anasetti,Joseph H. Antin,Stella M. Davies,Alexandra H. Filipovich,J Hegland,Naynesh Kamani,Nancy A. Kernan,Roberta King,Voravit Ratanatharathorn,Daniel J. Weisdorf,Dennis L. Confer +12 more
TL;DR: Age should be considered when selecting among comparably HLA-matched volunteer donors and the use of younger donors may lower the incidence of GVHD and improve survival after bone marrow transplantation.
Related Papers (5)
ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Jorg Dieter Seebach,Georg Stussi,Jakob Passweg,Fausto R. Loberiza,James Gajewski,Armand Keating,Martin Goerner,Philip A. Rowlings,Pierre Tiberghien,Gerald J. Elfenbein,Robert Peter Gale,Jon J. van Rood,Vijay Reddy,Eliane Gluckman,Brian J. Bolwell,Thomas R. Klumpp,Mary M. Horowitz,Olle Ringdén,A. John Barrett +18 more